艾德生物(300685) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥206,750,782.03, a decrease of 16.22% compared to the same period last year[8]. - Net profit attributable to shareholders was ¥134,870,084.05, representing a significant increase of 106.75% year-on-year[8]. - The net profit excluding non-recurring gains and losses was ¥44,512,268.54, down 27.10% from the previous year[8]. - Basic earnings per share were ¥0.34, up 112.50% year-on-year[8]. - Total operating revenue for the third quarter was ¥599,258,982.80, a decrease of 7.2% compared to ¥645,735,626.15 in the same period last year[31]. - The net profit for the current period reached CNY 224,157,836.85, an increase of 27% compared to CNY 176,496,035.76 in the previous period[34]. - Operating profit for the current period was CNY 256,234,697.00, up 30% from CNY 197,012,147.36 year-over-year[34]. - Total revenue from operating activities amounted to CNY 664,533,708.69, compared to CNY 601,563,244.71 in the previous period, reflecting a growth of approximately 10.5%[38]. - The basic and diluted earnings per share for the current period were both CNY 0.56, compared to CNY 0.44 in the previous period, representing a 27% increase[37]. - The company reported a total comprehensive income of CNY 224,506,263.64, compared to CNY 176,068,226.97 in the previous period, marking a significant increase[37]. Cash Flow and Liquidity - The company generated a net cash flow from operating activities of ¥145,723,486.86, an increase of 17.24% compared to the same period last year[8]. - Cash flow from operating activities netted CNY 145,723,486.86, an increase from CNY 124,291,686.18 in the previous period[41]. - The cash and cash equivalents at the end of the period were CNY 205,867,355.89, down from CNY 351,613,750.41, indicating a decrease in liquidity[41]. - The net increase in cash and cash equivalents was -29,921,267.86, reflecting a 200.80% decline, attributed to the increase in unexpired financial products[14]. - Investment activities resulted in a net cash outflow of CNY -104,574,928.34, compared to CNY -75,963,355.27 in the previous period, suggesting increased investment efforts[41]. - The company experienced a foreign exchange impact on cash and cash equivalents of CNY 29,793,579.12, contrasting with a negative impact of CNY -4,416,621.27 in the previous period[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,631,372,496.37, an increase of 7.34% from the end of the previous year[8]. - Total assets reached ¥1,631,372,496.37, up from ¥1,519,881,333.25, marking an increase of 7.3%[29]. - Total liabilities were reported at ¥149,736,431.01, a slight decrease from ¥150,250,223.95[29]. - The equity attributable to shareholders was ¥1,481,636,065.36, reflecting an increase of 8.58% year-on-year[8]. - Accounts receivable rose to ¥450,151,772.64, up from ¥428,771,096.72, indicating an increase of 4.5%[24]. - Inventory levels increased to ¥45,668,110.88 from ¥32,270,005.88, representing a significant rise of 41.7%[27]. Investments and Expenses - Financial expenses showed a significant decrease of 1425.13% to -30,268,298.24, primarily due to increased exchange gains[14]. - Investment income increased by 145.17% to 6,835,699.20, driven by higher returns from matured financial products[14]. - Research and development expenses increased to CNY 121,508,871.96, up from CNY 109,167,134.77, indicating a focus on innovation[34]. - Long-term deferred expenses increased by 162.90% to 2,703,377.58 due to increased laboratory construction investments[14]. - Deferred income tax assets decreased by 70.44% to 6,046,162.90 primarily due to a reduction in share-based payment tax assets[14]. - Other non-current assets rose by 98.48% to 12,255,949.00 mainly due to an increase in prepayments for long-term asset purchases[14]. Strategic Developments - The company completed the delivery of materials related to the SDC2 product and the transfer of intellectual property rights during the reporting period[11]. - The company completed the transfer of SDC2 product rights and equity in its subsidiary, indicating strategic market expansion efforts[23]. - The company plans to continue focusing on new product development and technology advancements to drive future growth[23]. - The company repurchased shares, resulting in treasury stock increasing by 137.54% to 77,818,281.09[14]. - The company reported a 5219.51% increase in asset disposal income to 94,550,129.44, primarily from the transfer of SDC2 products and related intellectual property[14]. Reporting and Auditing - The third quarter report of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. is unaudited[44]. - The board of directors released the third quarter report on October 25, 2022[44].